Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery
- PMID: 19183412
- DOI: 10.1111/j.1755-3768.2008.01433.x
Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery
Abstract
Purpose: This study compared the post-cataract surgery anti-inflammatory effects of topical treatment with 0.1% bromfenac, 0.1% betamethasone or both on postoperative anterior chamber inflammation and corneal swelling.
Methods: Seventy-two patients with no eye disease other than cataract were enrolled in a prospective, randomized study to undergo phacoemulsification combined with intraocular lens implantation. After cataract surgery, patients were randomized to treatment with bromfenac, betamethasone or both agents. Twenty-five eyes were assigned to bromfenac, 23 to betamethasone and 24 to the combined treatment group. Inflammatory reactions in the anterior chamber were measured with laser flare photometry preoperatively and at 1 and 3 days, 1 and 2 weeks, and 1 and 2 months postoperatively. Intraocular pressure (IOP) and corneal thickness were measured at the same time-points. Best corrected visual acuity (BCVA) was measured preoperatively and at 2 days, 1 and 2 weeks, and 1 and 2 months postoperatively. Specular microscope endothelial photography of the central region of the cornea was performed preoperatively and at 3 months after surgery.
Results: There were no significant differences among the bromfenac, betamethasone and combined treatment groups in BCVA, IOP, aqueous flare or corneal thickness. Cystoid macular oedema was present in one eye treated with betamethasone.
Conclusions: There were no significant differences in anti-inflammatory effects among the three treatments. These findings suggest that bromfenac is as effective as betamethasone in minimizing inflammatory reactions after cataract surgery.
Similar articles
-
Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation.Ophthalmology. 2007 Sep;114(9):1653-62. doi: 10.1016/j.ophtha.2006.12.029. Epub 2007 Apr 19. Ophthalmology. 2007. PMID: 17445902 Clinical Trial.
-
Safety and efficacy of bromfenac ophthalmic solution (Bromday) dosed once daily for postoperative ocular inflammation and pain.Ophthalmology. 2011 Nov;118(11):2120-7. doi: 10.1016/j.ophtha.2011.04.035. Epub 2011 Jul 16. Ophthalmology. 2011. PMID: 21762992 Clinical Trial.
-
[Minimally inflammatory cataract surgery].Klin Monbl Augenheilkd. 1996 Dec;209(6):331-9. doi: 10.1055/s-2008-1035330. Klin Monbl Augenheilkd. 1996. PMID: 9091708 Clinical Trial. German.
-
Ophthalmic utility of topical bromfenac, a twice-daily nonsteroidal anti-inflammatory agent.Expert Opin Pharmacother. 2009 Oct;10(14):2379-85. doi: 10.1517/14656560903188425. Expert Opin Pharmacother. 2009. PMID: 19735215 Review.
-
Global experience with Xibrom (bromfenac ophthalmic solution) 0.09%: the first twice-daily ophthalmic nonsteroidal anti-inflammatory drug.Int Ophthalmol Clin. 2006 Fall;46(4):21-40. doi: 10.1097/01.iio.0000212134.83513.11. Int Ophthalmol Clin. 2006. PMID: 17060789 Review. No abstract available.
Cited by
-
Bromfenac Ophthalmic Solution 0.07% Versus Nepafenac Ophthalmic Suspension 0.3% for Post-Cataract Surgery Inflammation: A Pilot Study of Identical Dosing Regimens with Pre-Surgical "Pulse" Dose.Ophthalmol Ther. 2019 Dec;8(4):577-587. doi: 10.1007/s40123-019-00215-y. Epub 2019 Sep 24. Ophthalmol Ther. 2019. PMID: 31552543 Free PMC article.
-
Corneal Edema after Cataract Surgery.J Clin Med. 2023 Oct 25;12(21):6751. doi: 10.3390/jcm12216751. J Clin Med. 2023. PMID: 37959216 Free PMC article. Review.
-
Non-steroidal anti-inflammatory drugs versus corticosteroids for controlling inflammation after uncomplicated cataract surgery.Cochrane Database Syst Rev. 2017 Jul 3;7(7):CD010516. doi: 10.1002/14651858.CD010516.pub2. Cochrane Database Syst Rev. 2017. PMID: 28670710 Free PMC article.
-
Prophylactic non-steroidal anti-inflammatory drugs for the prevention of macular oedema after cataract surgery.Cochrane Database Syst Rev. 2016 Nov 1;11(11):CD006683. doi: 10.1002/14651858.CD006683.pub3. Cochrane Database Syst Rev. 2016. PMID: 27801522 Free PMC article.
-
Comparison of Once-Daily Bromfenac 0.07% Versus Once-Daily Nepafenac 0.3% in Patients Undergoing Phacoemulsification.Ophthalmol Ther. 2019 Jun;8(2):261-270. doi: 10.1007/s40123-019-0174-x. Epub 2019 Mar 13. Ophthalmol Ther. 2019. PMID: 30868419 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources